2019-11-21 Gongwin-KY Aims at Huge Business Opportunities in Pet Cancer Market and Starts Pre-Expreiments Soon
Gongwin Biopharm Holdings Holdings Co., Ltd. (hereinafter referred to as "GongWin-KY", stock code: 6617) has recently obtained the approval for field experiments from the Bureau of Animal and Plant Health Inspection and Quarantine, COA, Executive Yuan (hereinafter referred to as the "Bureau of Animal Inspection"). It is expected to complete the experiments within one year, marking an important milestone by striving after the huge global animal cancer treatment market.
Gongwin-KY is a new drug development company currently listed on the Emerging Market of Taipei Exchange. Its core energy is the use of "mini-invasive targeted Chemo-Ablation Therapy" technology and direct injection of minimally invasive tumor-targeted ablation agents on the tumors, to achieve local tumor necrosis and apoptosis. At present, for PTS human drug series products, phase II liver cancer clinical trials are being performed in Taiwan, and the inspection and registration review on Class 1 new drugs are ongoing in China; in addition to the submission of IND application for phase II rare cancer clinical trials to the US FDA, globe-wide licensing activities for various cancer indications are also being actively launched. This time, the field experiment approved by Bureau of Animal Inspection is how Gongwin-KY has put its rich experiences in human anti-cancer drug development into new drug development work for animal drugs.
Gongwin-KY stated that, according to the foreign data compiled in the article "How much do you know about the pet economy? The development status and trends of pet food and health products" published by Research Division VII, Taiwan Institute of Economic Research, in July 2019, the Australian pet insurance company Bow Wow Meow Pet Insurance analyzed the number one common disease for dogs as cancer, and VetWest Animal Hospitals in Perth, Australia, compiled statistics showing that tumors were the second among the diseases for dogs and cats. Take Taiwan as an example, according to industry reports, the School of Veterinary Medicine, National Taiwan University, investigated the cause of death for domestic dogs and cats in Taipei City around 2012, and cancer was also the number one cause. According to public information from the domestic industry, cancer has risen to the top ten causes of death among elderly dogs and cats in the past decade. This is also when Palladia™, an anti-cancer targeted animal drug produced by Zoetis, listed on NASDAQ, was launched in 2009, and it soon met the market demand. However, up to now, there is still considerable market demand in the global companion animal anti-cancer drug market. This is due to the fact that the current treatment for companion animals suffering from cancer is mainly surgery + chemotherapy. As is known to all, this standard treatment is very harmful to animals, and it has been unable to meet the caring needs of people who consider dogs and cats as their family companions in the current societies of declining birth rate and ageing population. Gongwin-KY’s PTS drug has properties of targeted tumor ablation and will be able to meet this market trend.
Gongwin-KY pointed out that this approved canine field experiment will target malignant peripheral nerve sheath tumor (MPNST), oral malignant melanoma, bladder Cancer, lipoma and other indications which are currently important malignant diseases for dogs. Looking to the future, Gongwin-KY will continue to develop other common indications for dogs and cats. Gongwin-KY will take this new direction and aim to bring new treatment opportunities for the highly-socialized family companion animals around the globe. It is expected to complete the trials of some indications within one year to create overall operational contributions in the future.